Cargando…

Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication

BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Tani, Naoki, Ikematsu, Hideyuki, Goto, Takeyuki, Gondo, Kei, Inoue, Takeru, Yanagihara, Yuki, Kurata, Yasuo, Oishi, Ryo, Minami, Junya, Onozawa, Kyoko, Nagano, Sukehisa, Kuwano, Hiroyuki, Akashi, Koichi, Shimono, Nobuyuki, Chong, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578158/
https://www.ncbi.nlm.nih.gov/pubmed/36267253
http://dx.doi.org/10.1093/ofid/ofac493
_version_ 1784811912247115776
author Tani, Naoki
Ikematsu, Hideyuki
Goto, Takeyuki
Gondo, Kei
Inoue, Takeru
Yanagihara, Yuki
Kurata, Yasuo
Oishi, Ryo
Minami, Junya
Onozawa, Kyoko
Nagano, Sukehisa
Kuwano, Hiroyuki
Akashi, Koichi
Shimono, Nobuyuki
Chong, Yong
author_facet Tani, Naoki
Ikematsu, Hideyuki
Goto, Takeyuki
Gondo, Kei
Inoue, Takeru
Yanagihara, Yuki
Kurata, Yasuo
Oishi, Ryo
Minami, Junya
Onozawa, Kyoko
Nagano, Sukehisa
Kuwano, Hiroyuki
Akashi, Koichi
Shimono, Nobuyuki
Chong, Yong
author_sort Tani, Naoki
collection PubMed
description BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. METHODS: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2–naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. RESULTS: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48–6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. CONCLUSIONS: These results suggest an independent correlation between mRNA vaccine–induced specific IgG levels and post–booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers.
format Online
Article
Text
id pubmed-9578158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95781582022-10-19 Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication Tani, Naoki Ikematsu, Hideyuki Goto, Takeyuki Gondo, Kei Inoue, Takeru Yanagihara, Yuki Kurata, Yasuo Oishi, Ryo Minami, Junya Onozawa, Kyoko Nagano, Sukehisa Kuwano, Hiroyuki Akashi, Koichi Shimono, Nobuyuki Chong, Yong Open Forum Infect Dis Major Article BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. METHODS: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2–naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. RESULTS: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48–6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. CONCLUSIONS: These results suggest an independent correlation between mRNA vaccine–induced specific IgG levels and post–booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers. Oxford University Press 2022-09-23 /pmc/articles/PMC9578158/ /pubmed/36267253 http://dx.doi.org/10.1093/ofid/ofac493 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Tani, Naoki
Ikematsu, Hideyuki
Goto, Takeyuki
Gondo, Kei
Inoue, Takeru
Yanagihara, Yuki
Kurata, Yasuo
Oishi, Ryo
Minami, Junya
Onozawa, Kyoko
Nagano, Sukehisa
Kuwano, Hiroyuki
Akashi, Koichi
Shimono, Nobuyuki
Chong, Yong
Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title_full Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title_fullStr Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title_full_unstemmed Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title_short Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
title_sort correlation of postvaccination fever with specific antibody response to severe acute respiratory syndrome coronavirus 2 bnt162b2 booster and no significant influence of antipyretic medication
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578158/
https://www.ncbi.nlm.nih.gov/pubmed/36267253
http://dx.doi.org/10.1093/ofid/ofac493
work_keys_str_mv AT taninaoki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT ikematsuhideyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT gototakeyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT gondokei correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT inouetakeru correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT yanagiharayuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT kuratayasuo correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT oishiryo correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT minamijunya correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT onozawakyoko correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT naganosukehisa correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT kuwanohiroyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT akashikoichi correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT shimononobuyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication
AT chongyong correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication